Article in ChemistryOpen, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Daniel G SilvaQHeteM - Laboratório de Química Heterocíclica e Medicinal, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, 14040-903, Brazil.ORCID 0000-0001-8879-456X
Pim-Bart FeijensLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Wilrijk B, 2610, Belgium.
Rik HendrickxLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Wilrijk B, 2610, Belgium.
An MatheeussenLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Wilrijk B, 2610, Belgium.
Lucie GreyInstitute for Pharmaceutical and Medicinal Chemistry, Westphalian Wilhelms-University Münster, 48149, Münster, Germany.
Guy CaljonLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Wilrijk B, 2610, Belgium.ORCID 0000-0002-4870-3202
Louis MaesLaboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Wilrijk B, 2610, Belgium.ORCID 0000-0002-2324-9509
Flavio S EmeryQHeteM - Laboratório de Química Heterocíclica e Medicinal, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, São Paulo, 14040-903, Brazil.ORCID 0000-0002-8652-7123
Anna JunkerEuropean Institute for Molecular Imaging (EIMI), Westphalian Wilhelms-University Münster, 48149, Münster, Germany.ORCID 0000-0001-5151-0930
Funding
Conselho Nacional de Desenvolvimento Científico e Tecnológico 2017/21146-4Conselho Nacional de Desenvolvimento Científico e Tecnológico 2017/22001-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 313834/2018-0Conselho Nacional de Desenvolvimento Científico e Tecnológico 428527/2016-7Conselho Nacional de Desenvolvimento Científico e Tecnológico 88881.170193/2018-01Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - Brasil 001Fundacão de Amparo à Pesquisa do Estado de São Paulo
6 · The paper itself
Abstract
This study identified the isoindolone ring as a scaffold for novel agents against Trypanosoma brucei rhodesiense and explored the structure-activity relationships of various aromatic ring substitutions. The compounds were evaluated in an integrated in vitro screen. Eight compounds exhibited selective activity against T. b. rhodesiense (IC
Indexed as
AnimalsCell LineDrug StabilityFemaleHumansIsoindolesMiceMicrosomes, LiverMolecular StructureParasitic Sensitivity TestsSolubilityStructure-Activity RelationshipTrypanocidal AgentsTrypanosoma brucei rhodesienseIsoindolesTrypanocidal Agentsanti-infectivesheterocyclicin vitroT. b. bruceiT. b. rhodesiense
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Development of Novel Isoindolone-Based Compounds against Trypanosoma brucei rhodesiense. · full record | OpenQuestion